Trince
Venkata Varun Puppala started their work experience in 2014 with an in-plant training at Electronics Corporation of India Ltd. In 2022, they worked as a Software Engineer Intern at Terabee, where they integrated LoRaWAN software stack with FreeRTOS and analyzed the LoRaWAN specification. Following that, they joined Terabee again in 2022 as a Junior software specialist - embedded, where they successfully developed APIs for LoRaWAN communication and implemented code for sending AT command frames through UART. Currently, they are working at Trince as an Embedded Software Developer starting in 2023.
Venkata Varun Puppala has a strong educational background in electronics and engineering. Venkata Varun completed their Bachelor of Technology (B.Tech.) in Electrical, Electronics, and Communications Engineering from Vellore Institute of Technology, where they studied from 2013 to 2017. Subsequently, Venkata pursued a Master's degree in Electronics and Embedded Systems at ESIGELEC: ÉCOLE D'INGÉNIEURS-ES GÉNÉRALISTES, from 2020 to 2022.
Furthermore, Venkata has also obtained additional certifications to enhance their skill set. In December 2022, they completed the "Programming Foundations: Object-Oriented Design" certification from LinkedIn. Prior to that, in September 2019, they obtained a certification in "Linux Kernel" from the same institution.
Overall, Venkata Varun Puppala has a solid educational background in the field of electronics and engineering, complemented by certifications in programming and Linux kernel.
This person is not in any teams
Trince
Trince is a spin-off company from Ghent University dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. It can be used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology not only makes it easier to bring genetic material into cells in high-throughput. It also ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com